

Lilly Cares® Foundation 2021 State-Level Results



Diabetes Medications		
BAQSIMI® (glucagon) nasal powder; Basaglar® (insulin glargine injection); Glucagon™ (glucagon for injection); Humalog® (insulin lispro injection); Humulin® (human insulin); Lyumjev® (insulin lispro-aabc) injection; Trulicity® (dulaglutide) injection		
	Value of Medications based on Wholesale Acquisition Cost	Patients Served
AK	\$580,000	57
AL	\$31,200,000	3543
AR	\$9,100,000	919
AZ	\$14,400,000	1382
CA	\$36,700,000	3813
CO	\$7,500,000	749
CT	\$4,500,000	473
DC	\$200,000	26
DE	\$3,300,000	314
FL	\$71,000,000	7731
GA	\$57,600,000	6214
HI	\$880,000	59
IA	\$9,100,000	833
ID	\$7,600,000	839
IL	\$34,400,000	3166
IN	\$53,600,000	4919
KS	\$18,400,000	1987
KY	\$18,900,000	1835
LA	\$19,600,000	1949
MA	\$12,000,000	1113
MD	\$16,000,000	1575
ME	\$7,200,000	734
MI	\$49,100,000	4544
MN	\$16,600,000	1620
MO	\$37,500,000	3721
MS	\$14,600,000	1504
MT	\$3,700,000	366
NC	\$87,600,000	9084
ND	\$1,700,000	167
NE	\$13,200,000	1406
NH	\$6,700,000	607
NJ	\$13,500,000	1431
NM	\$3,300,000	342
NV	\$6,900,000	694
NY	\$29,800,000	2815
OH	\$78,600,000	7141
OK	\$19,700,000	2109
OR	\$13,700,000	1184
PA	\$48,800,000	4778
PR	\$270,000	36
RI	\$5,400,000	494
SC	\$26,100,000	2696
SD	\$2,800,000	307
TN	\$48,300,000	4689
TX	\$147,500,000	16046
UT	\$12,700,000	1255
VA	\$43,600,000	4817
VI	\$41,000	3
VT	\$750,000	77
WA	\$13,200,000	1269
WI	\$26,300,000	2471
WV	\$11,300,000	1074
WY	\$2,400,000	262

BAQSIMI®, Basaglar®, Humalog®, Humulin®, Lyumjev® and Trulicity® are registered trademarks and Glucagon™ is a trademark owned or licensed by Eli Lilly and Company, its subsidiaries or affiliates.

Lilly Cares® Foundation 2021 State-Level Results



Mental Health Medications		
Cymbalta® (duloxetine delayed-release capsules); Prozac® (fluoxetine); Strattera® (atomoxetine); Symbyax® (olanzapine and fluoxetine); Zyprexa® (olanzapine)		
	Value of Medications based on Wholesale Acquisition Cost	Patients Served
AL	\$4,400,000	937
AR	\$100,000	23
AZ	\$150,000	29
CA	\$370,000	81
CO	\$170,000	28
CT	\$48,000	10
DC	\$6,000	1
DE	\$34,000	8
FL	\$5,000,000	1211
GA	\$9,600,000	1780
HI	\$11,000	2
IA	\$76,000	17
ID	\$180,000	44
IL	\$380,000	77
IN	\$1,100,000	238
KS	\$2,600,000	485
KY	\$350,000	94
LA	\$380,000	85
MA	\$64,000	14
MD	\$250,000	52
ME	\$330,000	78
MI	\$460,000	107
MN	\$250,000	56
MO	\$2,800,000	551
MS	\$1,100,000	242
MT	\$270,000	53
NC	\$10,600,000	1987
ND	\$62,000	15
NE	\$1,100,000	245
NH	\$150,000	31
NJ	\$270,000	46
NM	\$43,000	8
NV	\$66,000	9
NY	\$450,000	55
OH	\$760,000	170
OK	\$11,400,000	2081
OR	\$250,000	60
PA	\$970,000	201
PR	\$8,000	1
RI	\$24,000	7
SC	\$1,100,000	231
SD	\$1,700,000	324
TN	\$3,300,000	574
TX	\$48,400,000	8846
UT	\$170,000	33
VA	\$4,300,000	884
VT	\$5,000	2
WA	\$260,000	43
WI	\$360,000	76
WV	\$330,000	67
WY	\$500,000	109

Cymbalta®, Prozac®, Strattera®, Symbyax®, and Zyprexa® are registered trademarks owned or licensed by Eli Lilly and Company, its subsidiaries or affiliates.

Lilly Cares® Foundation 2021 State-Level Results



Cancer Medications		
Alimta® (pemetrexed for injection); Cyramza® (ramucirumab) injection; Erbitux® (cetuximab) injection; Portrazza® (necitumumab) injection; Retevmo® (selpercatinib); Verzenio® (abemaciclib)		
	Value of Medications based on Wholesale Acquisition Cost	Patients Served
AK	\$480,000	5
AL	\$5,800,000	126
AR	\$3,200,000	57
AZ	\$10,300,000	133
CA	\$31,200,000	324
CO	\$6,400,000	74
CT	\$4,100,000	57
DC	\$230,000	3
DE	\$690,000	10
FL	\$40,100,000	548
GA	\$13,400,000	227
HI	\$1,900,000	20
IA	\$2,700,000	36
ID	\$2,500,000	26
IL	\$14,000,000	173
IN	\$9,500,000	115
KS	\$4,200,000	62
KY	\$5,100,000	61
LA	\$2,600,000	36
MA	\$6,400,000	67
MD	\$4,200,000	54
ME	\$2,500,000	26
MI	\$8,400,000	106
MN	\$8,300,000	98
MO	\$9,100,000	139
MS	\$4,700,000	56
MT	\$1,900,000	17
NC	\$14,800,000	208
ND	\$1,000,000	10
NE	\$3,000,000	34
NH	\$1,000,000	23
NJ	\$14,800,000	176
NM	\$1,500,000	14
NV	\$3,000,000	43
NY	\$18,400,000	238
OH	\$16,900,000	239
OK	\$5,000,000	79
OR	\$6,100,000	69
PA	\$16,900,000	238
PR	\$950,000	10
RI	\$770,000	13
SC	\$8,400,000	137
SD	\$360,000	4
TN	\$10,500,000	149
TX	\$48,600,000	672
UT	\$3,700,000	34
VA	\$14,100,000	192
VT	\$830,000	12
WA	\$8,100,000	101
WI	\$6,600,000	62
WV	\$3,100,000	42
WY	\$370,000	8

Alimta®, Cyramza®, Erbitux®, Portrazza®, Retevmo® and Verzenio® are registered trademarks owned or licensed by Eli Lilly and Company, its subsidiaries or affiliates.

Lilly Cares® Foundation 2021 State-Level Results



Other Medications

Cialis® (tadalafil); Emgality® (galcanezumab-gnlm) injection; Evista® (raloxifene hydrochloride); Forteo® (teriparatide injection); Humatrope® (somatropin) for injection; Olumiant® (baricitinib); REYVOW® (lasmiditan); Taltz® (ixekizumab) injection

	Value of Medications based on Wholesale Acquisition Cost	Patients Served
AK	\$1,100,000	25
AL	\$19,700,000	622
AR	\$22,000,000	422
AZ	\$15,400,000	412
CA	\$47,500,000	1274
CO	\$14,700,000	406
CT	\$4,500,000	121
DC	\$220,000	6
DE	\$3,300,000	67
FL	\$90,200,000	3159
GA	\$38,600,000	1096
HI	\$2,800,000	49
IA	\$6,700,000	195
ID	\$11,800,000	289
IL	\$25,500,000	599
IN	\$30,700,000	735
KS	\$10,900,000	268
KY	\$12,800,000	345
LA	\$20,100,000	492
MA	\$12,100,000	272
MD	\$7,500,000	211
ME	\$3,900,000	107
MI	\$26,900,000	655
MN	\$15,200,000	376
MO	\$27,300,000	764
MS	\$10,400,000	384
MT	\$3,700,000	94
NC	\$39,600,000	1240
ND	\$2,900,000	82
NE	\$5,000,000	159
NH	\$5,000,000	126
NJ	\$19,100,000	434
NM	\$2,900,000	69
NV	\$6,300,000	146
NY	\$27,300,000	647
OH	\$34,800,000	857
OK	\$17,600,000	447
OR	\$11,000,000	260
PA	\$28,700,000	773
PR	\$2,700,000	60
RI	\$2,200,000	57
SC	\$16,100,000	460
SD	\$4,000,000	117
TN	\$26,500,000	723
TX	\$98,200,000	2448
UT	\$9,100,000	251
VA	\$16,600,000	529
VT	\$700,000	23
WA	\$17,800,000	429
WI	\$16,400,000	444
WV	\$5,300,000	143
WY	\$1,100,000	41

Cialis®, Emgality®, Evista®, Forteo®, Humatrope®, Olumiant®, REYVOW® and Taltz® are registered trademarks owned or licensed by Eli Lilly and Company, its subsidiaries or affiliates.